Brain

 🎉 The CST Assistant v2.0 for Cognitive Stimulation Therapy (CST) now released in Denmark🇩🇰 🎉 ... UK here we come! 🇬🇧... I am so happy to bring the v2.0 to the market, as this  new version offers significant upgrades in terms of content, user interface and functionality. The v2.0 is available for existing customers and ready for introduction to new sales leads among Danish municipalities. The process of UK medical device certification of the English version of the CST Assistant v2.0 is progressing towards planned UK release end Q3 2024 This is what our Chief Strategy & Innovation Officer in Brain , Simon Nielsen says about the release: "The Danish release of version 2.0 of the CST Assistant is an important milestone in our quest to provide better treatment options for people with dementia. This new version has been developed in close collaboration with CST therapists and dementia experts in both Denmark and the UK – and we have been met with solid acknowledgement for the relevance of our offering. With the Danish release of this significantly upscaled product version now complete, our focus is on getting the English version certified for planned launch of the product in the UK as medical device before the end of Q3." Cognitive Stimulation Therapy & the v2.0 🧠 🌱 CST is the leading evidence-based non-pharmacological therapy for dementia, recommended by the World Alzheimer’s Association and the World Health Organization (WHO) for worldwide implementation. The release of version 2.0 introduces several new features and functional improvements aimed at making the preparation of CST sessions easier and faster, enhancing flexibility and fidelity in conducting the therapy, and offering an overall more personalized experience for CST therapists and people with dementia receiving CST. The WHY of Denmark 🇩🇰 and United Kingdom 🇬🇧 The Danish market is important to Brain in terms of valuable user input and learnings; however, it is small and without established reimbursement options for healthtech solutions, which makes adoption relatively slow. The company’s commercial focus is therefore on the UK market, which has higher healthtech readiness with established reimbursement pathways and the highest CST penetration globally. In the UK, CST is the only non-pharmacological therapy endorsed by the National Institute for Health and Care Excellence (NICE), and the National Health Service (NHS) Memory Services are obliged to offer CST to people diagnosed with dementia as part of the UK Memory Services National Accreditation Program (MSNAP). Onwards!

👁Q2 summary Q3 outlook!👁 In Brain , we have achieved important progress on all fronts in Q2. Businesswise, we have passed several milestones as we execute on our UK focused commercialization plan: 1) First of all, we completed the development of our CST-Assistant v 2.0 to support CST therapists and scale the delivery of Cognitive Stimulation Therapy (CST) to people with dementia. This is an essential step towards commercial release of the Danish product version in the coming days and of the English version for the UK market as a medical device towards the end of Q3. 2) We obtained supportive early user feedback in the ongoing usability study of the CST-Assistant conducted by AgeUK, which is progressing according to plan. Data from the study will feed into the UK certification of the product as medical device. 3) We applied for the CST-Assistant to be included on the digital procurement platform for the UK National Health Services (NHS) and we established a Brain UK subsidiary for access to UK NHS contracts and UK grants. 4) Under the grant funded CO-PI project for implementation of the CST-Assistant in Denmark, we held the first CST education sessions, including hands-on training of new CST therapists in the use of the CST-Assistant. This new approach has been met with strong interest from CST opinion leaders and trainers in the UK. 5) Finally, we recently informed of the hire of Devika Wood into a new position as Chief Commercial Officer. Devika is UK based and a recognized capacity in the health tech world, in particular in the UK. She has founded, built and commercialized health tech solutions with successful adoption into the NHS. Her hire marks the beginning of a new phase for Brain with focus on the commercialization of our products in Europe’s most attractive health tech market. In terms of financial position, we have closed our unit rights issue with gross proceeds of 6.0 million DKK, including strong backing from board and management as well as existing shareholders. During the public subscription period, we attracted further commitments, including from a specialized health tech investment boutique, called 5P, future of health. This marked the first ever institutional investment into Brain . The far majority of the guarantors of the transaction have opted to have their compensation fee paid in units to be issued in a directed issue under the same terms as in the public issue rather than in cash. This is a supportive sign of investor interest and commitment in the share. Q3 is all about preparations for UK medical device certification of the CST-Assistant and UK market entry. Activities to these ends include finalizing the UK version of the CST-Assistant, ensuring UK regulatory compliance, and certifying the product as medical-device-software with medical claims, while continuing to build customer interest and initiate potential sales dialogues. All this will be laying the ground for our 2024 main objective, first UK sales. Kim

🎉🎉🎉 We are at 66,6% (or 2/3rds) coverage with an additional 200.000 DKK top-guarantor! 💵🤝. The subscription period in the Rights Issue of units ends today, Monday 24 June 2024. Investors are advised to subscribe through their respective custodian bank or through Nordic Issuing AB. 📈 In our announcement from 20 June 2024, we informed that the Rights Issue was secured to 64.4% through subscription and guarantee commitments. With the additional to-down commitment from Naapster ApS, the Rights Issue is now secured to 66.6 percent. For complete information of the Rights Issue please see the company announcements from 7 and 22 May 2024, which can be found on Brain website. #DementiaManagement #digitalDementiaManagement #DigitalTherapy #DementiaCare #MentalHealthTech #DigitalHealth #Telehealth #VirtualTherapy #DigitalTherapeutics #DementiaSupport #HealthTech #ElderCare #CognitiveHealth #Telemedicine #AlzheimersCare #InnovationInHealthcare #DementiaTreatment #DigitalInnovation #RemoteTherapy #TechForGood #HealthcareTechnology #CognitiveTraining #dtx

I am happy to let you know that we got our first specialized digital health investment of DKK 372,000 (€50,000) from German, 5P Future of Health Beteiligungs GmbH, lifting the rights issue coverage to 64.4% by pre-subscription and guarantee commitments. 💵🤝 (note! LAST DAY on NORDNET)   I addition to this the Brain management topped up with additional investment of DKK 150.000. I have found another DKK 80,000 to commit, brining my total investment in the round up to 671,000 DKK (or 7.5% of the total issue). 💵🤝   We have this week incorporated Brain UK Limited, allowing us to access UK partnerships and grant funding to a new degree, and opening the doors to our go-to-market efforts. 🇬🇧    The rights issue is ongoing and has the last day of subscription on Monday, June 24., however, please notice that many banks have their last day today (incl. Nordnet) for subscribing to the rights issue.     We are working hard to realize our plans, and are on track for our UK launch, now with several more pieces in place! Onwards! Kim ABOUT 5P FUTURE OF HEALTH We are an early-stage investment boutique with an exclusive focus on Digital Health and Health TECH Startups.   We invest in transformative ideas in 5P medicine, which stands for: - PREVENTION - PREDICTIVE MEDICINE - PARTICIPATIVE HEALTH (democratization) - PRECISION MEDICINE - PROLONGED HEALTH (Healthy Longevity)   We operate out of Germany and invest in the DACH region as well as in startups with a link to Israel, Spain, including Latin America, and the US.   Our General Partners and Venture Partners are seasoned Health and TECH experts with well over 100 startups, 100 patents, and successful exits. We are also closely connected to clinical and research institutions as well as universities in different countries. #DementiaManagement #digitalDementiaManagement #DigitalTherapy #DementiaCare #MentalHealthTech #DigitalHealth #Telehealth #VirtualTherapy #DigitalTherapeutics #DementiaSupport #HealthTech #ElderCare #CognitiveHealth #Telemedicine #AlzheimersCare #InnovationInHealthcare #DementiaTreatment #DigitalInnovation #RemoteTherapy #TechForGood #HealthcareTechnology #CognitiveTraining #dtx Health Tech Hub Copenhagen

I'm thrilled to announce that Brain has officially established a subsidiary in the UK, Brain UK Limited! 🇬🇧 ... We are on track to our Q3 UK entry. This is a key step forward in our mission to become the leading provider of software-based dementia therapies. The UK is a perfect fit for us, with its: 🔬Strong focus on dementia research and care: The UK government prioritizes dementia, making it a receptive market for our solutions. 👩🔬Established healthcare system: The NHS, responsible for 80% of UK healthcare, presents vast commercial opportunities. 🏆 Recognition of Cognitive Stimulation Therapy (CST): The foundation of Brain 's products, CST originated in the UK and enjoys high adoption rates. Having a UK presence opens doors to: 🤝 Collaboration: We can work closely with leading UK healthcare institutions and researchers. 💵 Funding: Access to UK specific healthcare grants cab fund and accelerate our R&D and product launch timelines This is a pivotal moment for Brain , entering a major market like the UK. We're committed to bringing our non-drug dementia solutions to market faster,improving the lives of millions living with dementia. Onwards! #BrainPlus #DementiaCare #SoftwareTherapy #UKHealthcare #Innovation #DementiaManagement #digitalDementiaManagement #DigitalTherapy #DementiaCare #MentalHealthTech #DigitalHealth #Telehealth #VirtualTherapy #DigitalTherapeutics #DementiaSupport #HealthTech #ElderCare #CognitiveHealth #Telemedicine #AlzheimersCare #InnovationInHealthcare #DementiaTreatment #DigitalInnovation #RemoteTherapy #TechForGood #HealthcareTechnology #CognitiveTraining #dtx 

On my way to HLTH Europe 🇳🇱with Brain meeting partners collaborators and fellow companies on the journey into healthcare, connecting with new ones, and gaining new insights on the latest in market access, adoption into UK health care, and the latest from other European countries, the US and much more!! #HLTHEurope #HealthcareInnovation

Yesterday our talented Chief Financial Officer, Hanne Vissing Leth, presented Brain to a group of experienced life science investors... I am personally a big fan of Hannes measured and precise style of presenting what Brain is all about and also why its an interesting case for investors. Here you have the chance to watch the full presentation with Hanne: Brain  https://lnkd.in/d7Ueieuy #DementiaManagement #digitalDementiaManagement #DigitalTherapy #DementiaCare #MentalHealthTech #DigitalHealth #Telehealth #VirtualTherapy #DigitalTherapeutics #DementiaSupport #HealthTech #ElderCare #CognitiveHealth #Telemedicine #AlzheimersCare #InnovationInHealthcare #DementiaTreatment #DigitalInnovation #RemoteTherapy #TechForGood #HealthcareTechnology #CognitiveTraining #dtx

Subscription period has begun! 🌟 Join our webinar TODAY at 3pm CEST to get the latest update on Brain , ask questions, and hear about the offer. https://lnkd.in/dFz98jbR You can also read about the rights issue here https://lnkd.in/dnJckQcQ Best wishes, Kim

💰 Emissionstart! 🎯Investorupdate! 👁 Kort video! - hvad Frederecia terapeuter siger om CST-Assistent, inkl. produktdemo 💻 Det er spændende at vi imorgen starter vores tegningsperiode for vores emission. I relation til dette ønsker vi at give alle vores aktionærer og interessenter en chance for at få en opdatering og fokusere mere på detaljer om go-to-market og produktstrategi. Se detaljer om vores webinar nedenfor. Jeg vil også gerne here dele en ny video, hvor nogle af vores terapeutbrugere taler om deres oplevelse med CST-assistenten, hvor videoen også demonstrerer produktet. Investor Webinar 11/6 15:00 CEST Du inviteres til vores webinar, hvor vi bringer dig status for vores aktiviteter og dækker især vores fokuserede britiske kommercielle strategi, produktstrategi og udsigter for 2024. Tilmeld dig Investor Webinar: LINK I KOMMENTARER 2024 er et år med store milepæle, der giver adgang til et stort marked, Storbritanien, med enormt skaleringspotentiale for Brain , fra en stærk konkurrencedygtig position med alle de rigtige partnere, team og produkt til at lykkes. Vi ser frem til at diskutere dette på webinaret og gå ind på detaljer om ”hvad, hvornår, hvem, hvordan” af go-to-market-strategien. Tøv ikke med at kontakte mig, hvis du har spørgsmål om emissionen eller andet. Bedste ønsker, Kim #demensbehandling #digitaldemensbehandling #DigitalTerapi #Demensomsorg #MentalHealthTech #DigitalHealth #Telehealth #VirtualTherapy #DigitalTherapeutics #DemensSupport #HealthTech #Ældreomsorg #KognitivSundhed #Telemedicin #AlzheimersPleje #Velfærdsteknologi #Remote Sundhedsteknologi #Kognitivtræning #dtx 

💡Get the latest greatest on Brain , a summary of the company, business plan and timelines and terms of investment in relation to the soon upcoming rights issue.💰 ... I am myself investing another 600.000 DKK in the upcoming rights issue. The rights issue will open to public subscription from the 11-24th of June, and we already have 60% of the approximately 9 million DKK pre-committed This is the lowest valuation Brain has had since it was founded over 10 years ago, while we are stronger than ever, with a product that has proven demand in our home market, positive feedback from users and usability studies, endorsement and collaborations with the most important experts and KOLs, truly a dream team of talented individuals, and we are on track to enter the UK market in Q3 this year, UK is EUs largest and most mature market, both for our CST-Assistant product, and for digital health adoption into the National Health Services (NHS) generally, and we have all the right partners to succeed, who we evaluate to be the best of the best market access and commercial partners in the UK (@8fold and @Quiddity Health), a focused business plan and a go-to-market model that follows the best practice learnings and footsteps of previously succesfull digital health pioneers in the UK who are now market leading. If you have any questions about the rights issue and options to invest, don't hesitate to reach out to myself on [email protected] or to our great CFO, Hanne, at [email protected]. Onwards 🚀 Kim #DementiaManagement #digitalDementiaManagement #DigitalTherapy #DementiaCare #MentalHealthTech #DigitalHealth #Telehealth #VirtualTherapy #DigitalTherapeutics #DementiaSupport #HealthTech #ElderCare #CognitiveHealth #Telemedicine #AlzheimersCare #InnovationInHealthcare #DementiaTreatment #DigitalInnovation #RemoteTherapy #TechForGood #HealthcareTechnology #CognitiveTraining #dtx